戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ated with nelarabine (42% with v 81% without nelarabine).
2 lure were nonrandomly assigned to HDMTX plus nelarabine.
3 % for 38 stage two RER patients treated with nelarabine.
4 ay provide a predictive test for response to nelarabine.
5 h T-cell lymphoblastic lymphoma (T-LBL) with nelarabine.
6 xicity for clofarabine and neurotoxicity for nelarabine.
7 were nonrandomly assigned to ABFM C-MTX plus nelarabine.
8 rovide a prognostic test for the activity of nelarabine.
9  randomly assigned to receive or not receive nelarabine.
10                                              Nelarabine (1.2 g/m(2)) was infused on days 1, 3, and 5.
11 s compared with patients who did not receive nelarabine (1.3% +/- 0.63% v 6.9% +/- 1.4%, respectively
12 tropenic infections in patients treated with nelarabine (42% with v 81% without nelarabine).
13                                              Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-ar
14 armacokinetics of a novel purine nucleoside, nelarabine, a soluble prodrug of 9-beta-D-arabinosylguan
15 t significant adverse events associated with nelarabine administration are neurologic.
16  suggest the need for further exploration of nelarabine against fludarabine-refractory diseases.
17 or 16 stage one RER patients treated without nelarabine and 74% for 38 stage two RER patients treated
18 cified times for the determination of plasma nelarabine and ara-G concentrations.
19                   Pharmacokinetics of plasma nelarabine and arabinosylguanine (ara-G) and of cellular
20 cycle pharmacokinetic data, including plasma nelarabine and araG levels, were obtained on all patient
21  recent clinical trials incorporating use of nelarabine and bortezomib, choice of induction steroid,
22 ns for the use of novel therapies, including nelarabine and gamma-secretase inhibitors, in adult pati
23                      The pharmacokinetics of nelarabine and/or ara-G were evaluated in 71 patients (2
24  a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patien
25 ent cooperative groups, including the use of nelarabine, and provide rationales for current treatment
26                                              Nelarabine, as expected from its design, is a drug that
27 , all patients received six 5-day courses of nelarabine at 650 mg/m(2) once per day (10 SER patients
28                     Despite increased use of nelarabine-based chemotherapy consolidated by hematopoie
29 icant differences in the pharmacokinetics of nelarabine between any of the groups of patients.
30                           New agents such as nelarabine, bortezomib, and clofarabine may be effective
31                                              Nelarabine (compound 506U78), a water soluble prodrug of
32             For schedule A, patient received nelarabine daily for 5 days, whereas for schedule B, nel
33 se, prednisolone, mercaptopurine, dasatinib, nelarabine, daunorubicin, and inotuzumab ozogamicin) sho
34 odrug of 9-beta-D-arabinosylguanine (ara-G), nelarabine, demonstrated efficacy against T-cell acute l
35                                              Nelarabine did not show an advantage for HR patients.
36                                  The initial nelarabine dose was 1.2 g/m2 daily for 5 consecutive day
37  to 75 mg/kg and was linearly related to the nelarabine dose.
38  from 11.6 micromol/L to 308.7 micromol/L at nelarabine doses of 5 to 75 mg/kg and was linearly relat
39 onfirmed the effect of three purine analogs, nelarabine, fludarabine, and entecavir, showing the supp
40                                   The use of nelarabine for relapsed and refractory T-ALL results in
41                        Patients who received nelarabine had significantly fewer isolated and combined
42 ted with the best-performing arm, C-MTX plus nelarabine, had a 5-year DFS of 91% (n = 147).
43                                     Although nelarabine improved outcomes for those with CNS-3 status
44     We sought to define the response rate of nelarabine in children and young adults with refractory
45 oma (T-LL) and gained preliminary data using nelarabine in high-risk patients.
46        The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minu
47 tility of clofarabine in acute leukemias and nelarabine in T-cell diseases.
48 prodrug of 9-beta-D-arabinosylguanine (araG; Nelarabine), in pediatric and adult patients with refrac
49 to receive or not receive 6 5-day courses of nelarabine incorporated into ABFM.
50 mg/m(2)) was administered 4 hours before the nelarabine infusion.
51  of ara-G occurred at or near the end of the nelarabine infusion.
52                                              Nelarabine inhibited the formation of H3K9me3 on HIV gen
53                                              Nelarabine is a novel nucleoside with significant cytoto
54                                              Nelarabine is active as a single agent in recurrent T-ce
55                                              Nelarabine is an effective prodrug of ara-G, allowing sy
56                                              Nelarabine is an effective regimen against indolent leuk
57                             Fludarabine plus nelarabine is an effective, well-tolerated regimen again
58       For patients with relapsed T-cell ALL, nelarabine is available.
59                                              Nelarabine is effective in inducing remission in patient
60                                              Nelarabine is well tolerated and has significant antitum
61 was 73% versus 69% for those treated without nelarabine (n = 16).
62 for patients with T-ALL randomly assigned to nelarabine (n = 323) and no nelarabine (n = 336) were 88
63 omly assigned to nelarabine (n = 323) and no nelarabine (n = 336) were 88.2% +/- 2.4% and 82.1% +/- 2
64     Five-year EFS for all patients receiving nelarabine (n = 70) was 73% versus 69% for those treated
65 ept for significantly superior outcomes with nelarabine on AALL0434 (4-year disease-free survival, 93
66                                              Nelarabine, prodrug of arabinosylguanine (ara-G), has de
67 1), with no interactions between the MTX and nelarabine randomizations (P = .41).
68                         Both clofarabine and nelarabine recently received an accelerated approval by
69  receive or not receive six 5-day courses of nelarabine that was incorporated into ABFM.
70 to evaluate the efficacy of fludarabine with nelarabine (the prodrug of arabinosylguanine [ara-G]) in
71  assess the feasibility and safety of adding nelarabine to a BFM 86-based chemotherapy regimen in chi
72                                  Addition of nelarabine to a BFM 86-based chemotherapy regimen was we
73                              The addition of nelarabine to ABFM therapy improved DFS for children and
74 planned to determine whether the addition of nelarabine to front-line therapy for T-cell leukemia in
75 % for 22 stage two SER patients treated with nelarabine versus 69% for 16 stage one RER patients trea
76                                              Nelarabine was administered daily, as a 1-hour intraveno
77                                              Nelarabine was administered on an alternate day schedule
78 ne daily for 5 days, whereas for schedule B, nelarabine was administered on days 1, 3, and 5.
79                              Clofarabine and nelarabine were designed based on preclinical and clinic